3-(bromomethyl)-5-(4-fluorophenyl)-1,2-oxazole | 1267329-49-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(bromomethyl)-5-(4-fluorophenyl)-1,2-oxazole
• 英文别名: 3-(Bromomethyl)-5-(4-fluorophenyl)-1,2-oxazole
• CAS: 1267329-49-6
• 化学式: C₁₀H₇BrFNO
• 分子量: 256.074
• InChiKey: ATXGVLNFHSIBCC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(bromomethyl)-5-(4-fluorophenyl)-1,2-oxazole 在 盐酸 、 sodium hydride 、 sodium cyanoborohydride 作用下， 以 甲醇 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.75h， 生成 N-[3-[[5-(4-fluorophenyl)-1,2-oxazol-3-yl]methoxy]phenyl]-1-propan-2-ylpiperidine-4-carboxamide
  参考文献：
  名称：

  Biarylmethoxy isonipecotanilides as potent and selective inhibitors of blood coagulation factor Xa

  摘要：

  New chloro-substituted biarylmethoxyphenyl piperidine-4-carboxamides were synthesized and assayed in vitro as inhibitors of the blood coagulation enzymes factor Xa (fXa) and thrombin. An investigation of effects of the amidine and isopropyl groups attached at the piperidine nitrogen and 5-(halogenoaryl)isoxazol-3-yl groups as biaryl substituents led us to identify new compounds which proved to be selective fXa inhibitors, with inhibition constants in the low nanomolar range. The most potent compound 21e, that incorporates 2-Cl-thiophen-5-yl group as the P1 motif and 1-isopropylpiperidine P4 group, inhibited fXa with K-i value of 0.3 nM and very high selectivity over thrombin and some other tested serine proteases, achieving moderate levels of anticoagulant activity in the low micromolar range, as assessed by the prothrombin time clotting assay (PT2 = 3.30 mu M). Based on reliable docking simulations, molecular modeling provided a rationale for interpreting structure-activity relationships. The predicted binding modes highlighted the structural requirements for addressing the subsites S1 and S4 of the fXa enzyme. (C) 2010 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ejps.2010.11.010
• 作为产物：
  描述：

  4-(4-氟苯基)-2,4-二氧代丁酸乙酯 在 sodium tetrahydroborate 、 四溴化碳 、 盐酸羟胺 、 三苯基膦 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 34.0h， 生成 3-(bromomethyl)-5-(4-fluorophenyl)-1,2-oxazole
  参考文献：
  名称：

  Biarylmethoxy isonipecotanilides as potent and selective inhibitors of blood coagulation factor Xa

  摘要：

  New chloro-substituted biarylmethoxyphenyl piperidine-4-carboxamides were synthesized and assayed in vitro as inhibitors of the blood coagulation enzymes factor Xa (fXa) and thrombin. An investigation of effects of the amidine and isopropyl groups attached at the piperidine nitrogen and 5-(halogenoaryl)isoxazol-3-yl groups as biaryl substituents led us to identify new compounds which proved to be selective fXa inhibitors, with inhibition constants in the low nanomolar range. The most potent compound 21e, that incorporates 2-Cl-thiophen-5-yl group as the P1 motif and 1-isopropylpiperidine P4 group, inhibited fXa with K-i value of 0.3 nM and very high selectivity over thrombin and some other tested serine proteases, achieving moderate levels of anticoagulant activity in the low micromolar range, as assessed by the prothrombin time clotting assay (PT2 = 3.30 mu M). Based on reliable docking simulations, molecular modeling provided a rationale for interpreting structure-activity relationships. The predicted binding modes highlighted the structural requirements for addressing the subsites S1 and S4 of the fXa enzyme. (C) 2010 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ejps.2010.11.010

文献信息

• Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents
  作者：Burcu Çalışkan、Esra Sinoplu、Kübra İbiş、Ece Akhan Güzelcan、Rengül Çetin Atalay、Erden Banoglu

  DOI：10.1080/14756366.2018.1504041

  日期：2018.1.1

  In our endeavour towards the development of effective anticancer therapeutics, a novel series of isoxazole-piperazine hybrids were synthesized and evaluated for their cytotoxic activities against human liver (Huh7 and Mahlavu) and breast (MCF-7) cancer cell lines. Within series, compounds 5l-o showed the most potent cytotoxicity on all cell lines with IC50 values in the range of 0.3-3.7 μM. To explore

  在我们努力开发有效的抗癌疗法的过程中，合成了一系列新的异恶唑-哌嗪杂种，并评估了它们对人肝（Huh7和Mahlavu）和乳腺癌（MCF-7）癌细胞系的细胞毒活性。在系列中，化合物5l-o在所有细胞系中显示出最强的细胞毒性，IC50值在0.3-3.7μM的范围内。为了探究观察到的活性的基本机制，对肝癌细胞中5m和5o进行了进一步的生物学研究。我们已经证明5m和5o在足够的PTEN Huh7和PTEN不足的Mahlavu人肝癌细胞中诱导氧化应激，导致细胞凋亡和细胞周期停滞在不同阶段。
• 12,13-Aziridinyl Epothilones. Stereoselective Synthesis of Trisubstituted Olefinic Bonds from Methyl Ketones and Heteroaromatic Phosphonates and Design, Synthesis, and Biological Evaluation of Potent Antitumor Agents
  作者：K. C. Nicolaou、Derek Rhoades、Yanping Wang、Ruoli Bai、Ernest Hamel、Monette Aujay、Joseph Sandoval、Julia Gavrilyuk

  DOI：10.1021/jacs.7b02655

  日期：2017.5.31

  The synthesis and biological evaluation of a series of 12,13-aziridinyl epothilone B analogues is described. These compounds were accessed by a practical, general process that involved a 12,13-olefinic methyl ketone as a starting material obtained by ozonolytic cleavage of epothilone B followed by tungsten-induced deoxygenation of the epoxide moiety. The attachment of the aziridine structural motif

  描述了一系列 12,13-氮丙啶埃坡霉素 B 类似物的合成和生物学评价。这些化合物是通过一种实用的通用方法获得的，该方法涉及以 12,13-烯属甲基酮作为起始材料，通过臭氧分解埃坡霉素 B 然后钨诱导的环氧化物部分脱氧获得。氮丙啶结构基序的连接是通过应用 Ess-Kürti-Falck 氮丙啶化来实现的，而杂环侧链则是通过基于立体选择性膦酸酯的烯化作用引入的。为了确保后一种富电子杂环反应的高 (E) 选择性，有必要对古老的 Horner-Wadsworth-Emmons 反应进行前所未有的改进，使用 2-氟乙氧基膦酸酯，可能被证明在有机合成中具有普遍价值。这些研究导致发现了迄今为止报道的一些最有效的埃坡霉素。配备了适应现代药物递送技术的官能团，这些化合物中的一些表现出皮摩尔的效力，使它们成为抗体药物偶联物 (ADC) 的有效载荷，而其中一些化合物显示出令人印象深刻的抗耐药性人类癌细胞的活性，使其成为理想潜在的医疗应用。
• [EN] AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES<br/>[FR] ANALOGUES D'ÉPOTHILONE CONTENANT DE L'AZIRIDINE, PROCÉDÉS DE SYNTHÈSE, MÉTHODES DE TRAITEMENT, ET CONJUGUÉS MÉDICAMENTEUX DE CEUX-CI
  申请人：UNIV RICE WILLIAM M

  公开号：WO2018191394A1

  公开（公告）日：2018-10-18

  In one aspect, the present disclosure provides epothilone analogs of the formula: (I) wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein. Additionally, drug conjugates with cell targeting moieties of the compounds are also provided.

  在一个方面，本公开提供了公式为：(I)的紫杉醇类似物，其中变量如本文所定义。在另一个方面，本公开还提供了制备本文所披露化合物的方法。在另一个方面，本公开还提供了药物组合物和使用本文所披露化合物的方法。此外，还提供了具有细胞靶向基团的药物偶联物。
• AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES
  申请人：William Marsh Rice University

  公开号：EP3609538A1

  公开（公告）日：2020-02-19
• Biarylmethoxy isonipecotanilides as potent and selective inhibitors of blood coagulation factor Xa
  作者：Gianfranco Lopopolo、Filomena Fiorella、Modesto de Candia、Orazio Nicolotti、Sophie Martel、Pierre-Alain Carrupt、Cosimo Altomare

  DOI：10.1016/j.ejps.2010.11.010

  日期：2011.2

  New chloro-substituted biarylmethoxyphenyl piperidine-4-carboxamides were synthesized and assayed in vitro as inhibitors of the blood coagulation enzymes factor Xa (fXa) and thrombin. An investigation of effects of the amidine and isopropyl groups attached at the piperidine nitrogen and 5-(halogenoaryl)isoxazol-3-yl groups as biaryl substituents led us to identify new compounds which proved to be selective fXa inhibitors, with inhibition constants in the low nanomolar range. The most potent compound 21e, that incorporates 2-Cl-thiophen-5-yl group as the P1 motif and 1-isopropylpiperidine P4 group, inhibited fXa with K-i value of 0.3 nM and very high selectivity over thrombin and some other tested serine proteases, achieving moderate levels of anticoagulant activity in the low micromolar range, as assessed by the prothrombin time clotting assay (PT2 = 3.30 mu M). Based on reliable docking simulations, molecular modeling provided a rationale for interpreting structure-activity relationships. The predicted binding modes highlighted the structural requirements for addressing the subsites S1 and S4 of the fXa enzyme. (C) 2010 Elsevier B.V. All rights reserved.